| Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors | A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors | NCT06113016 |
| A Study of Fisetin to Treat Carpal Tunnel Syndrome | Phase 2 Clinical Trial of FIsetin to Treat CArpal Tunnel Syndrome (FITCATS) | NCT05416515 |
| Pharmacokinetics, safety, and efficacy of fisetin - A phase I and pilot phase IIa study | | CTIS2023-506284-34-00 |
| Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers | Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers | ChiCTR2500100733 |
| Fisetin to Reduce Senescence and Mobility Impairment in PAD | Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial | NCT06399809 |
| Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers | Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial | NCT06990256 |
| Fisetin to Improve Vascular Function in Older Adults | Clinical Translation of Senolytic Therapy with Fisetin to Improve Vascular Function in Older Adults | NCT06133634 |
| Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease | Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies | NCT07025226 |
| A Comparison of Fisetin Kinetics in Young and Old Adults | A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1 | NCT06796374 |
| COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes | COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes | NCT04537299 |
| COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation | COVID-FISETIN: a Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults | NCT04476953 |
| Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | AFFIRM-LITE: a Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | NCT03675724 |
| Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | AFFIRM: a Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | NCT03430037 |
| COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications | COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients | NCT04771611 |
| Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors | NCT05595499 |
